Breast Cancer related Tumor Profiling Service
With our advanced platform of Tumor Profiling to Guide Targeted Cancer Therapy, Creative Biolabs has developed an unparalleled platform for tumor profiling in breast cancer. To fulfill every need of our consumers, our professional scientists are ready to start working on your projects.
Introduction of Tumor Profiling in Breast Cancer
Tumor profiling in breast cancer is crucial for guiding personalized treatments by identifying specific genetic and molecular alterations, such as HER2 amplification or BRCA mutations. It predicts responses to targeted therapies, like HER2 inhibitors, and assesses hormone receptor status to optimize endocrine treatments. The heterogeneity of breast cancer is fundamentally important for tumor development, progression, and drug resistance. By uncovering tumor heterogeneity, profiling also helps prevent resistance and relapse. Recently, tumor profiling on genomic and proteomic levels has been developed to decipher the heterogeneity of breast cancer. A comprehensive tumor profiling could help broaden the treatment options, improve the therapeutic effectiveness, and reduce exposure to adverse effects.
Fig.1
Potentially actionable alterations in breast cancer samples.1
Advances in Breast Tumor Profiling
Creative Biolabs has developed well-established platforms for your oncology research.
Technologies and biomarker panels for tumor profiling in breast cancer provide us insight into the heterogeneity among breast tumor cell populations and facilitate our cancer study. There is a table that includes the technologies and biomarker panels available at Creative Biolabs for profiling 10 different cancers, including breast cancer, non-small cell lung cancer, colorectal cancer, etc. You can get specific information for any type of tumor that you are interested in. These technologies and biomarkers include but are not limited to:
| Well-studied Biomarkers | ||||
|---|---|---|---|---|
| Technologies | Genetic | Chromosomal | Transcriptional | Proteomic |
| Breast Cancer | ||||
|
NGS ISH PCR IHC Microarray |
BRAF TP53 EGFR BRCA1/2 KRAS ERBB2/4 CDH1 MET CDK12 PTEN FGFR1/2/3 HRAS CHEK1/2 PIK3CA ATM |
MET PTEN |
HER2 ER PR |
PD-L1 22C3 Pan-TRK |
| Non-Small Cell Lung Cancer (NSCLC) | ||||
|
NGS FISH PCR IHC Microarray FC IF |
STK11 AKT1 EGFR BRAF KRAS ERBB2/4 TP53 MET FGFR1/2/3 CCND1 PTEN HRAS RB1 PIKЗCA ATM |
ALK MET PTEN RET |
VEGFA |
PD-L1 HER2 Pan-TRK |
| Colorectal Cancer | ||||
|
NGS FISH IHC FC LC-MS |
ALK AKT1 EGFR BRAF KRAS ERBB2/4 TP53 MET FGFR1/2/3 NOTCH1 PTEN ROS1 RB1 PIK3CA ATM |
ALK MET PTEN RET ROS1 |
PD-L1 |
PD-L1 HER2 Pan-TRK |
| Melanoma Cancer | ||||
|
NGS FISH PCR IHC Microarray FC |
AKT1 EGFR BRAF ERBB2/4 FGFR1/2/3 MET PDFFRA NRAS KIT CDK4 |
PTEN | MITF |
PD-L1 Pan-TRK |
| Pancreatic Cancer | ||||
|
NGS FISH PCR IHC Microarray |
Gene Variations KRAS TP53 SMAD4 CDKN2A RREB1 KDM6A RAC1 ARMET BRAF TGFBR2 ACVR1B MAP3K21 RAS ARMET RNF43 |
Chr 1~22 and Chr X, insertions, deletions, duplications, inversions and translocations |
MicroRNAs, Long noncoding RNAs, DNA methylation |
CA 19-9 |
| Brain Cancer | ||||
|
NGS ISH PCR IHC Microarray |
EGFR TP53 IDH1 EPHB2 APC MYC MLHI BAP1 SMAD4 COL4A1 ERBB2 HRAS AKT1 CDKN2B EPCAM |
CDKN2A(p16) deletion EGFR amplification MET amplification CDKN2A (p16) deletion |
ALK RAF1 BRAF ROS1 EGFR FGFR1 |
GFAP S100B |
| Ovarian Cancer | ||||
|
NGS FISH PCR IHC Microarray RT-PCR ELISA Whole Transcriptome Sequencing DNA Methylation |
CTNNB1 PRKN TP53 PIKЗCA OPCML AKTI CDH1 ERBB2 RRAS2 PARK2 BRCA1/2 STK11 CDKN2B EPCAM |
hyper- and hypo-methylation: OPCML DCR1 RASSF1A BRCA1 histone modification and miRNAs: Sirtuin-1 TGF |
Cytokines/Chemokines: MFAP2 SEMG2 DLK1 Pro-apoptotic Proteins: NTNG1 CA-125 ILs XCL1 Angiogenic factors: CXCL7 VEGF EGFR ErbB2 |
|
| Endometrial Cancer | ||||
|
NGS FISH PCR IHC Microarray FC IF RT-PCR ELISA |
BRAF PIKЗCA APC BRCA1/2 SMAD4 HRAS TP53 CDH1 EGFR EPCAM KIT PTEN ESR1 MSH2/6 NRAS PDGFRA SMO SMARCA4 ATM FGFR1/2/3 |
MET PTEN |
PD-L1 |
HER2 PDL1 |
| Thyroid Cancer | ||||
|
NGS FISH PCR IHC Microarray |
TP53 KRAS ERBB2/4 ALK ATM BRAF CDKN2A RET PIK3CA SMO CDKN2A PTEN SMAD4 HRAS CTNNB1 |
MET RET |
PD-L1 |
Pan-TRK PD-L1 |
| Head and Neck Cancer | ||||
|
NGS FISH PCR IHC Microarray IF ELISA |
PTEN TP53 PTEN KRAS EGFR CTNNB1 BRAF PIK3CA ERBB2 FGFR1/2/3 CDKN2A NOTCH1 AKT1 RB1 ATM |
MET PTEN RET |
PD-L1 |
Pan-TRK PD-L1 |
Tumor Profiling in Breast Cancer Is Used for
Personalized Cancer Treatment
Creative Biolabs offers comprehensive tumor profiling services to support personalized cancer treatment, including genomic, transcriptomic, and proteomic analyses. These services aim to optimize therapeutic strategies by identifying actionable biomarkers and understanding tumor heterogeneity.
Learn More →Diagnostic Tool
We provide tumor profiling services as a diagnostic tool, offering genomic, transcriptomic, and proteomic analyses to enhance cancer diagnosis and treatment strategies by identifying key biomarkers and molecular alterations.
Learn More →Biomarker Discovery
Creative Biolabs offers tumor profiling services for biomarker discovery, utilizing advanced genomic, transcriptomic, and proteomic analyses to identify novel biomarkers, accelerating cancer research, and enabling the development of targeted therapies.
Learn More →Prognostic Assessment
We can provide tumor profiling services for prognostic assessment, helping predict disease outcomes by analyzing key biomarkers and molecular signatures, and supporting personalized treatment strategies and clinical decision-making.
Learn More →Simplified Workflow for Breast Tumor Profiling
If you have any specific requirements for the whole profiling process, please do not hesitate to get in touch with us and our professional experts can tailor the tumor profiling services according to your needs.
Get Your Tailored Service Now
Why Choose Us?
Ready to Get an Instant Quote?
Trust Creative Biolabs to deliver tailored solutions, offering precise and actionable insights to support every step of your immuno-oncology research journey.
Reference
- Kawaji, Hitomi, et al. "Comprehensive molecular profiling broadens treatment options for breast cancer patients." Cancer medicine 10.2 (2021): 529-539. Distributed under Open Access license CC BY 4.0, without modification.
